1. Home
  2. AIDX vs CALC Comparison

AIDX vs CALC Comparison

Compare AIDX & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIDX

20/20 Biolabs Inc. Common Stock

N/A

Current Price

$0.95

Market Cap

9.2M

Sector

Health Care

ML Signal

N/A

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.90

Market Cap

9.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIDX
CALC
Founded
N/A
2011
Country
United States
United States
Employees
14
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2M
9.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AIDX
CALC
Price
$0.95
$0.90
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
241.0K
296.5K
Earning Date
N/A
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.30
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.97
Revenue Growth
N/A
N/A
52 Week Low
$0.78
$0.46
52 Week High
$14.09
$7.20

Technical Indicators

Market Signals
Indicator
AIDX
CALC
Relative Strength Index (RSI) 37.43 58.19
Support Level N/A $0.52
Resistance Level $1.66 $0.93
Average True Range (ATR) 0.11 0.12
MACD 0.03 0.01
Stochastic Oscillator 51.61 50.12

Price Performance

Historical Comparison
AIDX
CALC

About AIDX 20/20 Biolabs Inc. Common Stock

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: